{"id":"W2120171585","doi":"10.1016/j.ejca.2013.02.012","title":"Phase I–IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours","year":2013,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; Ottawa Hospital","funders":"","keywords":"Medicine; Erlotinib; Rash; T790M; Pharmacodynamics; Pharmacokinetics; Adverse effect; Pharmacology; Internal medicine; Epidermal growth factor receptor; Cohort; Discontinuation; Oncology; Cancer; Gefitinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007691698,0.0002115443,0.0005913328,0.0003286367,0.00004270214,0.00004760268,0.0001460245,0.00001379087,0.0001888175],"category_scores_gemma":[0.0001528894,0.0001390341,0.00002654818,0.0003802154,0.000112602,0.0003537927,0.00008144047,0.0003574748,0.000004464539],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001311949,"about_ca_system_score_gemma":0.0002445763,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001924702,"about_ca_topic_score_gemma":0.0002949343,"domain_scores_codex":[0.9976003,0.0004156758,0.0006662238,0.0002630542,0.0007288755,0.0003258863],"domain_scores_gemma":[0.9982056,0.00004502074,0.0003012674,0.0002402374,0.0006634512,0.0005444475],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.0192914,0.008055232,0.4320484,0.0003930554,0.000321256,0.001913535,0.009575479,0.000248469,0.01187062,0.000001899061,0.002099326,0.5141813],"study_design_scores_gemma":[0.06160844,0.07858177,0.8497117,0.001724263,0.0002444833,0.0000820909,0.003118109,0.00009589472,0.002522509,0.000004681049,0.001967581,0.0003385087],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9973969,0.0008707579,0.0000209001,0.0004605603,0.0001134673,0.001020409,0.00001352559,0.000006807633,0.00009667974],"genre_scores_gemma":[0.9980294,0.000134522,0.001263513,0.0002332087,0.0001145834,0.00001603744,0.000001728719,0.00006627673,0.0001407623],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5138428,"threshold_uncertainty_score":0.5669645,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03850557109698171,"score_gpt":0.3869098973173942,"score_spread":0.3484043262204125,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}